Trial Profile
A Phase I/II Trial Investigating the Combination of Pembrolizumab (Keytruda) With Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Lenalidomide (Primary) ; Pembrolizumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms MUKfourteen
- 22 Aug 2017 Status changed from not yet recruiting to withdrawn prior to enrolment due to withdrawal of pharma support prior to opening to recruitment
- 21 Jun 2017 New trial record